The availability of a Covid-19 vaccine will be a “significant factor” in more than six in 10 organizations’ decisions to resume business travel, according to a new survey of travel managers and procurement professionals by the Global Business Travel Association.
About 61 percent of the 353 respondents polled online Dec. 7-14 by GBTA indicated vaccine availability would be a “significant factor” in that decision-making process, while another 23 percent called it a “moderate factor.” Only 2 percent of respondents thought vaccines wouldn’t be a factor, while the rest didn’t know.
A Covid-19 vaccine developed by Pfizer and BioNTech has been approved for emergency use in several countries, including the United States, Canada, the United Kingdom and the European Union. A second vaccine, developed by Moderna, has been approved by the U.S. for emergency use. Approvals for other vaccines are pending; China and Russia have approved vaccines developed in those countries. U.S. distribution . . .